Get the Stockscreener App
0.3389
3.12%
-0.0109
After Hours:
.34
0.0011
+0.32%
Mereo Biopharma Group Plc Adr stock is traded at $0.3389, with a volume of 977.57K.
It is down -3.12% in the last 24 hours and down -12.20% over the past month.
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
See More
Previous Close:
$0.3498
Open:
$0.3442
24h Volume:
977.57K
Relative Volume:
0.07
Market Cap:
$54.09M
Revenue:
$506.20K
Net Income/Loss:
$-42.05M
P/E Ratio:
-1.2803
EPS:
-0.2647
Net Cash Flow:
$-31.36M
1W Performance:
-6.04%
1M Performance:
-12.20%
6M Performance:
-82.53%
1Y Performance:
-85.70%
1-Day Range:
$0.3302
$0.3653
1-Week Range:
$0.3293
$0.3734
52-Week Range:
$0.20
$3.05
Mereo Biopharma Group Plc Adr Stock (MREO) Company Profile
Name
Mereo Biopharma Group Plc Adr
Sector
Industry
Phone
4403330237300
Address
ONE CAVENDISH PLACE, LONDON
Compare MREO vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MREO
Mereo Biopharma Group Plc Adr
|
0.3389 | 55.83M | 506.20K | -42.05M | -31.36M | -0.2647 |
VRTX
Vertex Pharmaceuticals Inc
|
453.74 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
756.73 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
692.83 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
147.60 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Mereo Biopharma Group Plc Adr Stock (MREO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-30-25 | Downgrade | Jefferies | Buy → Hold |
| Mar-27-25 | Initiated | JP Morgan | Overweight |
| Dec-06-24 | Initiated | Jefferies | Buy |
| Jun-13-24 | Initiated | Robert W. Baird | Outperform |
| Oct-13-23 | Resumed | BTIG Research | Buy |
| Aug-12-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-05-21 | Initiated | BTIG Research | Buy |
| Apr-05-21 | Initiated | Needham | Buy |
View All
Mereo Biopharma Group Plc Adr Stock (MREO) Latest News
Mereo BioPharma Group plcSponsored ADR (NASDAQ:MREO) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
MREO Deadline: MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit - Barchart.com
MREO Investor AlertMereo BioPharma Group plc Investors with Large Losses Should Contact Robbins LLP for Information About the Securities Fraud Class Action Lawsuit - ChartMill
MREO Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Mereo BioPharma Group plc Securities Lawsuit -- The Gross Law Firm - Sahm
Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.
MREO SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026 - ChartMill
Baird reiterates Mereo BioPharma stock rating after earnings By Investing.com - Investing.com South Africa
MREO Stock Price, Quote & Chart | MEREO BIOPHARMA GROUP PL-ADR (NASDAQ:MREO) - ChartMill
MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm - Barchart
MREO DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026 - Sahm
Leerink reiterates Outperform on Mereo BioPharma stock at $2 By Investing.com - Investing.com South Africa
Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights - Investing News Network
Mereo BioPharma (NASDAQ: MREO) details 2025 loss and cash runway to 2027 - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines – MREO - FinancialContent
MREO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Mereo (MREO) Investors of Securities Class Action Deadline on April 6, 2026 - Barchart
MREO DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Mereo (MREO) Investors of Securities Class Action Deadline on April 6, 2026 - ChartMill
MREO SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds Mereo (MREO) Investors of Securities Class Action Deadline on April 6, 2026 - Barchart.com
MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit - Barchart.com
Class Action Filed Against Mereo BioPharma Group plc (MREO)April 6, 2026 Deadline to JoinContact The Gross Law Firm - Barchart
Pomerantz LLP Issues Reminder to Investors in Mereo BioPharma Group plc of Class Action Filing – MREO - ACCESS Newswire
MREO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Mereo BioPharma Investors of Securities Class Action Deadline on April 6, 2026 - Barchart.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming DeadlinesMREO - Sahm
UPCOMING DEADLINE: Mereo BioPharma (MREO) Securities Fraud Class Action – April 6, 2026 Lead Plaintiff DeadlineFaruqi & Faruqi LLP - ChartMill
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 6, 2026 in Mereo LawsuitMREO - Barchart.com
MREO SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026 - Barchart.com
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 6, 2026 in Mereo BioPharma Group plc LawsuitMREO - Barchart.com
Shareholders who lost money in shares of Mereo BioPharma Group PLC (NASDAQ: MREO) should contact Wolf Haldenstein immediately - ChartMill
NASDAQ: MREO INVESTOR ALERT: Berger Montague Advises Mereo BioPharma Group PLC (NASDAQ: MREO) Investors of an April 6, 2026 Deadline - ChartMill
Pomerantz Law Firm Reminds Investors with Losses on their Investment in Mereo BioPharma Group plc of Class Action Lawsuit and Upcoming Deadlines – MREO - marketscreener.com
Nasdaq bid-price warning puts Mereo BioPharma (NASDAQ: MREO) listing at risk - Stock Titan
Mereo BioPharma Faces Securities Litigation - Intellectia AI
Mereo Biopharma Group Plc Adr Stock (MREO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.04%
0.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):